Arthritis and rheumatism
-
Arthritis and rheumatism · Sep 2013
Randomized Controlled Trial Multicenter StudyEfficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). ⋯ In patients with active LN, overall renal response rates with ocrelizumab were numerically but not statistically significantly superior to those with placebo. Ocrelizumab treatment was associated with a higher rate of serious infections in the subgroup receiving background MMF.